Credit Suisse Group set a GBX 1,300 ($18.23) price objective on GlaxoSmithKline (LON:GSK) in a research note released on Thursday morning. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts have also recently weighed in on GSK. Deutsche Bank restated a hold rating and set a GBX 1,610 ($22.57) price objective on shares of GlaxoSmithKline in a research note on Wednesday, October 11th. Jefferies Group upped their price objective on GlaxoSmithKline from GBX 1,675 ($23.49) to GBX 1,700 ($23.84) and gave the stock a buy rating in a research note on Monday, October 16th. Goldman Sachs Group restated a buy rating and set a GBX 1,900 ($26.64) price objective on shares of GlaxoSmithKline in a research note on Tuesday, October 17th. Morgan Stanley set a GBX 1,600 ($22.43) price target on GlaxoSmithKline and gave the company a sell rating in a research note on Wednesday, October 18th. Finally, Shore Capital reiterated a hold rating on shares of GlaxoSmithKline in a research note on Monday, October 23rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of Hold and a consensus price target of GBX 1,541.36 ($21.61).

Shares of GlaxoSmithKline (GSK) traded down GBX 12.80 ($0.18) during midday trading on Thursday, hitting GBX 1,291 ($18.10). The company had a trading volume of 11,683,099 shares, compared to its average volume of 9,220,000. The stock has a market cap of $64,010.00 and a PE ratio of 4,164.52. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($17.32) and a 1 year high of GBX 1,724.50 ($24.18).

GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, February 7th. The company reported GBX 111.80 ($1.57) earnings per share for the quarter, topping analysts’ consensus estimates of GBX 110.90 ($1.55) by GBX 0.90 ($0.01). The firm had revenue of GBX 763.90 billion during the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

In other news, insider Sir Roy Anderson bought 562 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The shares were acquired at an average price of GBX 1,278 ($17.92) per share, for a total transaction of £7,182.36 ($10,070.61). Also, insider Patrick Vallance sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of GBX 1,310 ($18.37), for a total value of £262,000 ($367,358.38). Over the last three months, insiders acquired 581 shares of company stock worth $743,284.

WARNING: “Credit Suisse Group Reiterates GBX 1,300 Price Target for GlaxoSmithKline (GSK)” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2018/02/09/credit-suisse-group-reiterates-gbx-1300-price-target-for-glaxosmithkline-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.